Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - Hepion Pharmaceuticals, Inc. | tm2034164d6_ex5-1.htm |
| EX-4.8 - EXHIBIT 4.8 - Hepion Pharmaceuticals, Inc. | tm2034164d6_ex4-8.htm |
| EX-4.7 - EXHIBIT 4.7 - Hepion Pharmaceuticals, Inc. | tm2034164d6_ex4-7.htm |
| EX-1.1 - EXHIBIT 1.1 - Hepion Pharmaceuticals, Inc. | tm2034164d6_ex1-1.htm |
| S-1/A - S-1/A - Hepion Pharmaceuticals, Inc. | tm2034164d6_s1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Hepion Pharmaceuticals, Inc.
Edison, New Jersey
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 (Amendment No. 3) of our report dated May 14, 2020, relating to the consolidated financial statements of Hepion Pharmaceuticals, Inc., appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Woodbridge, New Jersey
November 20, 2020